WASHINGTON — A briefing document given to the Food and Drug Administration’s advisory panel that approved last week emergency use of the Pfizer jab for kids 5 to 11 shows that what was approved was a modified formula that was not used in clinical trials.
As reported this week, the Centers for Disease Control provided the final approval needed to inject kids.
In the FDA document, it states on page 14 that there was an amendment requested which states: “To provide a vaccine with an improved stability profile, the Pfizer-BioNTech COVID-19 vaccine for use in children 5-11 years of age uses tromethamine (Tris) buffer instead of the phosphatebuffered saline (PBS) as used in the previous formulation and excludes sodium chloride and potassium chloride.”
The Exposé reported on this modification notes that the addition of Tris is to reduce “the acidity of blood” and to lessen the effects of those who have heart attacks. It is extremely uncommon for children to have heart attacks, but there have been increased numbers of heart conditions and myocarditis since the COVID-19 jabs have been use, including in children who have been jabbed. Tris has a list of side effects itself, detailed by The Exposé.
“If Pfizer believes that their vaccine was safe why have they changed the formulation? The authorization for the EUA being requested is not for the formulation that had been tested in the clinical trials, what has been requested is ‘a modified formulation of the Pfizer‑BioNTech COVID-19 vaccine,” The Exposé states.
The CDC claims the jab is 90.7% effective for children, which is “meaningless,” The Exposé states since its hard to measure the effectiveness considering the extreme low risk kids face from COVID-19 to begin with. It stated: “The rates in 5 to 11 are so low that there were no “cases” of severe COVID-19 or death from either the treatment (n= 1,518) or control group (n= 750), this renders the “90% effective” claim, meaningless. This should have stopped an EUA application in its tracks, as clearly there is no emergency for this age group in particular and therefore no benefit either.”
Additionally, the FDA took action months before this approval that suggests it was preparing for increased heart problems among kids. In June, the FDA approved the “First Oral Blood Thinning Medication for Children,” it’s press release headline states.
Andrew White, for the National File, wrote: “In late June 2021, the Food and Drug Administration (FDA) approved a drug called Pradaxa; oral pellets to treat children 3 months to less than 12 years of age with venous thromboembolism, a condition that involves blood clots forming in the veins …. A few months later, the FDA authorized children ages 5-11 to be injected with the Pfizer COVID-19 shot.”
As these actions should cause concerns for parents, the propaganda campaign is rolling out. Pfizer just released a “Creepy” advertisement, as stated by Matt Agorist for the Free Thought Project.
“The multibillion dollar pharma giant with an incredibly tainted past, who has seen exponential profits during the pandemic as a result of taxpayers being forced to pay for the jab, has also enjoyed billions in taxpayer dollars to advertise said jab,” Agorist wrote. “The windfall of profits realized from vaccinating adults quickly turned the company’s sights to children as their customer base waned. Despite children facing a near zero chance of dying from COVID-19, the FDA jumped on board and quickly approved Pfizer’s mRNA vaccine for children ages 5-11.”
Agorist added: “After spending billions in taxpayer funded advertisements to convince adults to take the jab, Pfizer launched a new ad this week, which seemingly targets their new customer base — children. The company held back nothing and referred to children who got the vaccine as part of the experiment as ‘superheroes’ with ‘superpowers.’”
Support The Liberty Loft by donating via PayPal or donating with crypto. Your support helps us achieve our mission to deliver conservative news and opinion. You can find us on a wide variety of social media channels or subscribe to our notifications to receive all the latest information as it is released.